CD276 and cancer: Those experiencing cancer progression following anti-PD1 therapy demonstrated distinct immunological profiles, marked by deficiencies in macrophage, monocyte, and T follicular helper responses, compromised antigen presentation, aberrant Tregs response, and elevated expression of immunosuppressive molecules such as TGFB, IL2RA, and CD276.